Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Jul;46(4):705-719.
doi: 10.1002/jimd.12602. Epub 2023 Mar 13.

Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: A phase 2, open label, multicenter study

Nathalie Guffon  1 , Vassiliki Konstantopoulou  2 , Julia B Hennermann  3 , Nicole Muschol  4 , Irene Bruno  5 , Albina Tummolo  6 , Ferdinando Ceravolo  7 , Giulia Zardi  8 , Andrea Ballabeni  7 , Allan Lund  9   10
Affiliations
Clinical Trial

Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: A phase 2, open label, multicenter study

Nathalie Guffon et al. J Inherit Metab Dis. 2023 Jul.

Abstract

Alpha-mannosidosis (AM) is a rare, autosomal recessive, lysosomal storage disorder caused by alpha-mannosidase deficiency that leads to the accumulation of mannose-rich oligosaccharides. AM symptoms and severity vary among individuals; consequently, AM is often not diagnosed until late childhood. Velmanase alfa (VA), a recombinant human lysosomal alpha-mannosidase product, is the first enzyme replacement therapy indicated to treat non-neurological symptoms of AM in Europe. Previous studies suggested that early VA treatment in children may produce greater clinical benefit over the disease course than starting treatment in adolescents or adults; however, long-term studies in children are limited, and very few studies include children under 6 years of age. The present phase 2, multicenter, open-label study evaluated the safety and efficacy of long-term VA treatment in children under 6 years of age with AM. Five children (three males) received VA weekly for ≥24 months, and all children completed the study. Four children experienced adverse drug reactions (16 events) and two experienced infusion-related reactions (12 events). Most (99.5%) adverse events were mild or moderate, and none caused study discontinuation. Four children developed antidrug antibodies (three were neutralizing). After VA treatment, all children improved in one or more efficacy assessments of serum oligosaccharide concentrations (decreases), hearing, immunological profile, and quality of life, suggesting a beneficial effect of early treatment. Although the small study size limits conclusions, these results suggest that long-term VA treatment has an acceptable safety profile, is well tolerated, and may provide potential benefits to patients with AM under 6 years of age.

Keywords: alpha-mannosidosis; antidrug antibody; endurance; oligosaccharides; pharmacokinetics; physical functioning; velmanase alfa.

PubMed Disclaimer

References

REFERENCES

    1. Malm D, Nilssen O. Alpha-mannosidosis. Orphanet J Rare Dis. 2008;3:21.
    1. Borgwardt L, Stensland HMFR, Olsen KJ, et al. Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation. Orphanet J Rare Dis. 2015;10:70.
    1. Borgwardt L, Guffon N, Amraoui Y, et al. Health related quality of life, disability, and pain in alpha mannosidosis: long-term data of enzyme replacement therapy with velmanase alfa (Human recombinant alpha mannosidase). J Inborn Errors Metab Screen. 2018;6.
    1. Berg T, Riise HM, Hansen GM, et al. Spectrum of mutations in alpha-mannosidosis. Am J Hum Genet. 1999;64(1):77-88.
    1. Malm D, Halvorsen DS, Tranebjaerg L, Sjursen H. Immunodeficiency in alpha-mannosidosis: a matched case-control study on immunoglobulins, complement factors, receptor density, phagocytosis and intracellular killing in leucocytes. Eur J Pediatr. 2000;159:699-703.

Publication types

LinkOut - more resources